Taysha Dividend Paid And Capex Coverage Ratio from 2010 to 2024
| TSHA Stock | USD 3.24 0.24 8.00% |
Dividend Paid And Capex Coverage Ratio | First Reported 2010-12-31 | Previous Quarter (9.91) | Current Value (10.40) | Quarterly Volatility 2.38255502 |
Check Taysha Gene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Taysha Gene's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 5.2 M or Selling General Administrative of 26.5 M, as well as many indicators such as Price To Sales Ratio of 12.64, Dividend Yield of 0.0 or PTB Ratio of 2.88. Taysha financial statements analysis is a perfect complement when working with Taysha Gene Valuation or Volatility modules.
Taysha | Dividend Paid And Capex Coverage Ratio |
Latest Taysha Gene's Dividend Paid And Capex Coverage Ratio Growth Pattern
Below is the plot of the Dividend Paid And Capex Coverage Ratio of Taysha Gene Therapies over the last few years. It is Taysha Gene's Dividend Paid And Capex Coverage Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Taysha Gene's overall financial position and show how it may be relating to other accounts over time.
| Dividend Paid And Capex Coverage Ratio | 10 Years Trend |
|
Dividend Paid And Capex Coverage Ratio |
| Timeline |
Taysha Dividend Paid And Capex Coverage Ratio Regression Statistics
| Arithmetic Mean | (4.43) | |
| Coefficient Of Variation | (53.73) | |
| Mean Deviation | 1.66 | |
| Median | (3.38) | |
| Standard Deviation | 2.38 | |
| Sample Variance | 5.68 | |
| Range | 7.0165 | |
| R-Value | (0.65) | |
| Mean Square Error | 3.51 | |
| R-Squared | 0.43 | |
| Significance | 0.01 | |
| Slope | (0.35) | |
| Total Sum of Squares | 79.47 |
Taysha Dividend Paid And Capex Coverage Ratio History
About Taysha Gene Financial Statements
Taysha Gene stakeholders use historical fundamental indicators, such as Taysha Gene's Dividend Paid And Capex Coverage Ratio, to determine how well the company is positioned to perform in the future. Although Taysha Gene investors may analyze each financial statement separately, they are all interrelated. For example, changes in Taysha Gene's assets and liabilities are reflected in the revenues and expenses on Taysha Gene's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Taysha Gene Therapies. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Dividend Paid And Capex Coverage Ratio | (9.91) | (10.40) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Taysha Gene Therapies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Taysha Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Taysha Gene Therapies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Taysha Gene Therapies Stock:Check out the analysis of Taysha Gene Correlation against competitors. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taysha Gene. If investors know Taysha will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Taysha Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.63 | Revenue Per Share 0.042 | Quarterly Revenue Growth (0.62) | Return On Assets (0.27) | Return On Equity (1.15) |
The market value of Taysha Gene Therapies is measured differently than its book value, which is the value of Taysha that is recorded on the company's balance sheet. Investors also form their own opinion of Taysha Gene's value that differs from its market value or its book value, called intrinsic value, which is Taysha Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taysha Gene's market value can be influenced by many factors that don't directly affect Taysha Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Taysha Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taysha Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taysha Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.